A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Status:
Recruiting
Trial end date:
2022-11-25
Target enrollment:
Participant gender:
Summary
To characterize safety and tolerability and identify a recommended dose and regimen for the
LXH254 in combination with LTT462 or trametinib or ribociclib.